Stemline initiated with an Overweight at Piper Jaffray. Piper Jaffray analyst Joseph Catanzaro started Stemline Therapeutics with an Overweight rating and $20 price target. The analyst believes the company’s Phase II data in blastic plasmacytoid dendritic cell neoplasm support a full U.S. approval and “robust adoption” into this setting that could drive U.S. sales in excess of $250M by 2027. Further, he adds that tagraxofusp has reported “very encouraging clinical activity.” Catanzaro expects Stemline shares to appreciate over the next 12 months
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.